Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSF1 | Q00613 | 1/20 | 0.67 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | WEE1 | P30291 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787116 | 0.83 | HSF1 (0.70) | HSF1ROCK2BRD4ROCK1EGFR | |
| SCHEMBL6789752 | 0.81 | HSF1 (0.67) | HSF1ROCK2ROCK1EGFR | |
| SCHEMBL29695497 | 0.81 | HSF1 (1.00) | HSF1ROCK2BRD4ROCK1EGFR | |
| SCHEMBL6783318 | 0.81 | HSF1 (1.00) | HSF1ROCK2BRD4ROCK1EGFR | |
| SCHEMBL29380539 | 0.81 | HSF1 (1.00) | HSF1ROCK2BRD4ROCK1EGFR | |
| SCHEMBL9985254 | 0.79 | HSF1 (0.80) | HSF1ROCK2BRD4ROCK1EGFR | |
| SCHEMBL6782658 | 0.78 | HSF1 (0.78) | HSF1ROCK2BRD4ROCK1MKNK1 | |
| SCHEMBL6789472 | 0.77 | HSF1 (0.74) | HSF1ROCK2BRD4ROCK1WEE1 | |
| SCHEMBL6793978 | 0.77 | HSF1 (0.73) | HSF1ROCK2BRD4ROCK1MKNK1 | |
| SCHEMBL9985222 | 0.76 | HSF1 (0.76) | HSF1ROCK2BRD4ROCK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306641-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL PREPARATION INCLUDING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2011-12-15 | — | — | US | claimed |
| US-20110306641-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL PREPARATION INCLUDING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306641-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL PREPARATION INCLUDING SAME | PTMS, NOS3, NOS1 | HSF1 4573/4885ROCK2 841/4885BRD4 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.